Korro Bio (KRRO) risk factors, FY2025 10-K

Korro Bio's FY2025 10-K, filed Mar 12, 2026, lists 94 risk factors in 6 groups. Against the prior year's 99: 8 new, 13 dropped, 33 substantially reworded.

Open KRRO in Gloom →
Korro Bio's chart, financials and news, free in your browser.Open KRRO in Gloom →
Risk factors listed
946 groups
New this year
8vs 99 last year
Dropped
13since the prior 10-K
Substantially reworded
33of those kept
Section length
40k wordsItem 1A

What the changes say

  • Korro Bio faces severe concentration risk on lead candidate KRRO-121 targeting hyperammonemia, with a planned IND filing in the second half of 2026.

What changed since the prior 10-K

New

  • NewRisks Related to Our Business

    Our business is substantially dependent on the success of KRRO-121, our lead development candidate, and if KRRO-121 fails to advance successfully, our business would be materially and adversely affected

    Our business depends heavily on our lead preclinical candidate, KRRO-121, for hyperammonemia including UCD and HE, which we plan to file for human trials in late 2026.

  • NewRisks Related to Discovery, Development and Commercialization

    clinically important effects, nor that the data generated by our preclinical studies can translate into positive results in clinical trials

    All our programs are in research or preclinical stages, and we previously experienced setbacks like those in our REWRITE Phase 1/2a clinical trial.

  • NewRisks Related to Discovery, Development and Commercialization

    Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations

    Healthcare reforms, prescription drug pricing rules, and cost-containment measures in the U.S. and abroad could restrict our ability to profitably sell approved products.

  • NewRisks Related to Discovery, Development and Commercialization

    the availability of capital

    A 2024 U.S. Supreme Court decision creates regulatory uncertainty and litigation risk that could complicate FDA reviews and policymaking.

  • NewRisks Related to Regulatory, Legal, and Clinical Trials

    misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans

    We and our vendors face cyberattacks and insider threats, potentially enhanced by artificial intelligence, risking our trade secrets and financial data.

  • NewRisks Related to Intellectual Property

    more of our products or certain aspects of our platform technology. Further, a court or administrative body could construe certain patent claims narrowly or refuse to prevent the other party from using the technology at issue on the ground that our patents do not cover the technology

    Courts or administrative bodies may find our patent claims invalid or too narrow to stop competitors from using our technology.

  • NewRisks Related to Intellectual Property

    the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects

    Geopolitical actions and the European Unified Patent Court could increase patent prosecution costs and allow third parties to seek revocation of European patents.

  • NewRisks Related to Intellectual Property

    Our business may be impacted by macroeconomic conditions, including inflation, rising interest rates and volatile market conditions, and other uncertainties beyond our control, including geopolitical events, such as recent U.S. and Israeli military action in Iran, and effects thereof

    Macroeconomic volatility, inflation, rising interest rates, and geopolitical events such as U.S. and Israeli military action in Iran could impair our fundraising ability.

Dropped

  • DroppedRisks Related to Our Business

    Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates

  • DroppedRisks Related to Discovery, Development and Commercialization

    In addition, although we believe OPERA, our RNA editing platform, will position us to expand our portfolio of product candidates beyond the initial product candidates we may develop, we have not yet successfully developed any product candidate and our ability to expand our portfolio may never materialize

  • DroppedRisks Related to Discovery, Development and Commercialization

    authorities in other countries or jurisdictions. Approval processes vary among countries and can involve additional product candidate testing and validation and additional administrative review periods

  • DroppedRisks Related to Discovery, Development and Commercialization

    European Union, or EU, and Australia, where we recently dosed the first participants in our Phase 1/2a REWRITE clinical trial of KRRO-110 for AATD

  • DroppedRisks Related to Regulatory, Legal, and Clinical Trials

    Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set

  • DroppedRisks Related to Regulatory, Legal, and Clinical Trials

    certain safe-use criteria, and requiring treated patients to enroll in a registry, among other requirements. These limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors

    Preclinical and clinical data are often susceptible to varying interpretations and analyses.

  • DroppedRisks Related to Regulatory, Legal, and Clinical Trials

    Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business

  • DroppedRisks Related to Regulatory, Legal, and Clinical Trials

    exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified

  • DroppedRisks Related to Regulatory, Legal, and Clinical Trials

    civil and criminal penalties, up to and including criminal prosecution resulting in fines, exclusion from healthcare reimbursement programs and imprisonment

  • DroppedRisks Related to Our Third Party Relationships

    We may not be successful in finding strategic collaborators for continuing development of certain of our product candidates or successfully commercializing or competing in the market for certain indications; and we may not see any benefit from our collaboration agreement with Novo Nordisk

    OPERA RNA editing platform expansion plans may never materialize.

  • DroppedRisks Related to Our Third Party Relationships

    Some state laws also require pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures

    Foreign authorities have varying approval processes and commercialization requires manufacturing supply.

  • DroppedRisks Related to Intellectual Property

    confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, our competitive position could be harmed

  • DroppedRisks Related to Intellectual Property

    Our business may be impacted by macroeconomic conditions, including fears concerning the financial services industry, inflation, rising interest rates and volatile market conditions, and other uncertainties beyond our control

Reworded

  • 99% rewrittenRisks Related to Regulatory, Legal, and Clinical Trials

    The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our development candidates could limit our product revenues

    Updated to emphasize that genetic-based development candidates face uncertain foreign and domestic pricing controls, reimbursement, and pricing review periods.

    Was: The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue

  • 92% rewrittenRisks Related to Regulatory, Legal, and Clinical Trials

    If we or our collaborators, manufacturers, service providers or other third parties fail to comply with applicable healthcare laws and regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation

    Expanded to specifically list anti-kickback restrictions, false claims, patient privacy, and anti-bribery laws alongside increased government scrutiny of interactions with providers.

  • 84% rewrittenRisks Related to Regulatory, Legal, and Clinical Trials

    We may not be able to obtain orphan drug exclusivity for one or more of our development candidates, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products

    Changed references from product candidates to development candidates regarding orphan drug exclusivity with the FDA and EMA.

    Was: We may not be able to obtain orphan drug exclusivity for one or more of our product candidates, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products

  • 82% rewrittenRisks Related to Regulatory, Legal, and Clinical Trials

    We may be unable to adequately protect our information systems from cybersecurity incidents or data breaches, which could result in the disclosure of confidential information, damage our reputation, and subject us to significant financial and legal exposure

    Added specific mention of ransomware, phishing attacks, wrongful conduct by employees or vendors, and human error as cybersecurity threats.

    Was: We may be unable to adequately protect our information systems from cybersecurity incidents, which could result in the disclosure of confidential information, damage our reputation, and subject us to significant financial and legal exposure

  • 77% rewrittenRisks Related to Our Third Party Relationships

    We expect to rely on third parties to conduct our clinical trials and some aspects of our research, as well as some aspects of our delivery methods, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing

    Added that third-party reliance includes supplying key materials for our programs in addition to conducting preclinical animal experiments.

  • 77% rewrittenRisks Related to Intellectual Property

    We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful

    Updated terminology from product candidates to development candidates in the context of patent infringement counterclaims.

  • 70% rewrittenRisks Related to Discovery, Development and Commercialization

    We are very early in our development efforts, and our preclinical studies and clinical trials may not be successful. If we are unable to commercialize our development candidates or experience significant delays in doing so, our business will be materially harmed

    Updated to disclose the termination of the Phase 1/2a REWRITE trial of KRRO-110 for AATD and introduce the KRRO-121 2026 regulatory timeline.

    Was: We are very early in our development efforts, and our preclinical studies and clinical trials may not be successful. If we are unable to commercialize our product candidates or experiences significant delays in doing so, our business will be materially harmed

  • 60% rewrittenRisks Related to Regulatory, Legal, and Clinical Trials

    We may be unable to obtain regulatory approval in the United States or foreign jurisdictions and, as a result, be unable to commercialize our development candidates and our ability to generate revenue will be materially impaired

    Replaced references of product candidates with development candidates regarding extensive governmental regulations.

    Was: We may be unable to obtain regulatory approval in the United States or foreign jurisdictions and, as a result, be unable to commercialize our product candidates and our ability to generate revenue will be materially impaired

  • 59% rewrittenRisks Related to Regulatory, Legal, and Clinical Trials

    Because we are developing oligonucleotides, which are considered a relatively new class of drugs, there is increased risk that the outcome of our clinical trials will not be sufficient to obtain regulatory approval

  • 58% rewrittenRisks Related to Our Business

    We will need substantial additional funding. If we are unable to raise capital when needed, we will be forced to delay, reduce, eliminate or prioritize among our research and development programs or future commercialization efforts

  • 57% rewrittenRisks Related to Our Business

    We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability

  • 56% rewrittenRisks Related to Our Business

    operate as a public company

  • 56% rewrittenRisks Related to Regulatory, Legal, and Clinical Trials

    Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our development candidates outside the United States

    Was: Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States

  • 50% rewrittenRisks Related to Regulatory, Legal, and Clinical Trials

    We, our collaborators and our service providers may be subject to a variety of privacy and data security laws, regulations and contractual obligations, and our failure to comply with them could harm our business

  • 46% rewrittenRisks Related to Intellectual Property

    Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our RNA editing platform technology, lead candidates and development candidates

    Was: Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our RNA editing platform technology and product candidates

  • 44% rewrittenRisks Related to Our Personnel, Operations and Growth

    We expect to need to expand our research, development, delivery, manufacturing, commercialization, regulatory and future sales and marketing capabilities over time, and as a result, we may encounter difficulties in managing our future growth, which could disrupt our operations

    Was: We expect to expand our research, development, delivery, manufacturing, commercialization, regulatory and future sales and marketing capabilities over time, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations

  • 42% rewrittenRisks Related to Our Business

    If we experience delays or difficulties in the enrollment of patients in clinical trials, or other delays in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented

  • 41% rewrittenRisks Related to Discovery, Development and Commercialization

    If we cannot successfully manufacture our development candidates for our research and development and preclinical activities, or manufacture sufficient amounts of our development candidates to meet our clinical requirements and timelines, our business may be materially harmed

    Was: If we cannot successfully manufacture our product candidates for our research and development and preclinical activities, or manufacture sufficient amounts of our product candidates to meet our clinical requirements and timelines, our business may be materially harmed

  • 36% rewrittenRisks Related to Intellectual Property

    Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition

  • 30% rewrittenRisks Related to Discovery, Development and Commercialization

    Our development candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences

    Was: Our product candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences

  • 29% rewrittenRisks Related to Our Third Party Relationships

    We rely on third parties in the supply and manufacture of our lead candidates and development candidates for our research, preclinical and clinical activities, and may do the same for commercial supplies of our lead or development candidates

    Was: We rely on third parties in the supply and manufacture of our product candidates for our research, preclinical and clinical activities, and may do the same for commercial supplies of our product candidates

  • 29% rewrittenRisks Related to Discovery, Development and Commercialization

    We may expend our limited resources to pursue a particular development candidate or indication and fail to capitalize on development candidates or indications that may be more profitable or for which there is a greater likelihood of success

    Was: We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success

  • 28% rewrittenRisks Related to Our Business

    changes in regulatory requirements and guidance that require amending or submitting new clinical protocols

  • 28% rewrittenRisks Related to Discovery, Development and Commercialization

    varying interpretations of data by the FDA and similar foreign regulatory agencies

  • 23% rewrittenRisks Related to Discovery, Development and Commercialization

    Any development candidates we develop may fail in preclinical or clinical development or be delayed to a point where they do not become commercially viable

    Was: Any product candidates we develop may fail in preclinical or clinical development or be delayed to a point where they do not become commercially viable

  • 23% rewrittenRisks Related to Our Business

    attract top talent and retain qualified personnel

  • 23% rewrittenRisks Related to Discovery, Development and Commercialization

    establishment and maintenance of healthcare coverage and adequate reimbursement by payors

  • 23% rewrittenRisks Related to Discovery, Development and Commercialization

    we may not realize the full commercial potential of any development candidates we develop that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our products

    Was: we may not realize the full commercial potential of any product candidates we develop that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our products

  • 21% rewrittenRisks Related to Regulatory, Legal, and Clinical Trials

    Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a development candidate and the approval may be for a narrower indication than we seek

    Was: Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek

  • 21% rewrittenRisks Related to Intellectual Property

    If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed

  • 21% rewrittenRisks Related to Discovery, Development and Commercialization

    collaborative arrangements in our target markets with leading companies and research institutions

  • 20% rewrittenRisks Related to Discovery, Development and Commercialization

    RNA editing is a novel technology with limited clinical validation for human therapeutic use. The approaches we take to discover and develop novel therapeutics are unproven and may never lead to marketable products

  • 20% rewrittenRisks Related to Our Business

    We have never generated revenue from product sales and may never become profitable

All 94 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Business

  1. 01We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability57% rewritten
  2. 02operate as a public company56% rewritten
  3. 03We have never generated revenue from product sales and may never become profitable20% rewritten
  4. 04attract top talent and retain qualified personnel23% rewritten
  5. 05We will need substantial additional funding. If we are unable to raise capital when needed, we will be forced to delay, reduce, eliminate or prioritize among our research and development programs or future commercialization efforts58% rewritten
  6. 06changes in regulatory requirements and guidance that require amending or submitting new clinical protocols28% rewritten
  7. 07experience damage to our reputation
  8. 08Our business is substantially dependent on the success of KRRO-121, our lead development candidate, and if KRRO-121 fails to advance successfully, our business would be materially and adversely affectedNew
  9. 09If we experience delays or difficulties in the enrollment of patients in clinical trials, or other delays in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented42% rewritten

Risks Related to Discovery, Development and Commercialization

  1. 10clinically important effects, nor that the data generated by our preclinical studies can translate into positive results in clinical trialsNew
  2. 11RNA editing is a novel technology with limited clinical validation for human therapeutic use. The approaches we take to discover and develop novel therapeutics are unproven and may never lead to marketable products20% rewritten
  3. 12We are very early in our development efforts, and our preclinical studies and clinical trials may not be successful. If we are unable to commercialize our development candidates or experience significant delays in doing so, our business will be materially harmed70% rewritten
  4. 13establishment and maintenance of healthcare coverage and adequate reimbursement by payors23% rewritten
  5. 14Any development candidates we develop may fail in preclinical or clinical development or be delayed to a point where they do not become commercially viable23% rewritten
  6. 15varying interpretations of data by the FDA and similar foreign regulatory agencies28% rewritten
  7. 16We may not be able to conduct clinical trials successfully due to various process-related factors that could negatively impact our business plans
  8. 17If we cannot successfully manufacture our development candidates for our research and development and preclinical activities, or manufacture sufficient amounts of our development candidates to meet our clinical requirements and timelines, our business may be materially harmed41% rewritten
  9. 18The process of manufacturing oligonucleotides is complex and we may encounter difficulties in production, particularly with respect to process development or scaling-up of our manufacturing capabilities
  10. 19We may expend our limited resources to pursue a particular development candidate or indication and fail to capitalize on development candidates or indications that may be more profitable or for which there is a greater likelihood of success29% rewritten
  11. 20Our development candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences30% rewritten
  12. 21If we are unable to successfully identify patients who are likely to benefit from therapy with any development candidates we develop, or experience significant delays in doing so, we may not realize the full commercial potential of any products we may develop
  13. 22we may not realize the full commercial potential of any development candidates we develop that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our products23% rewritten
  14. 23If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any development candidates, we may be unable to generate any revenues
  15. 24Even if we receive regulatory approval to market our development candidates, the market may not be receptive to our development candidates upon their commercial introduction, which will prevent us from becoming profitable
  16. 25The pharmaceutical industry is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to commercialize successfully any drugs that we develop
  17. 26collaborative arrangements in our target markets with leading companies and research institutions21% rewritten
  18. 27Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operationsNew
  19. 28the availability of capitalNew
  20. 29If the market opportunities for any development candidates we may develop are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer

Risks Related to Regulatory, Legal, and Clinical Trials

  1. 30Because we are developing oligonucleotides, which are considered a relatively new class of drugs, there is increased risk that the outcome of our clinical trials will not be sufficient to obtain regulatory approval59% rewritten
  2. 31Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a development candidate and the approval may be for a narrower indication than we seek21% rewritten
  3. 32the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
  4. 33We may be unable to obtain regulatory approval in the United States or foreign jurisdictions and, as a result, be unable to commercialize our development candidates and our ability to generate revenue will be materially impaired60% rewritten
  5. 34injunctions or the imposition of civil or criminal penalties
  6. 35The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our development candidates could limit our product revenues99% rewritten
  7. 36We may not be able to obtain orphan drug exclusivity for one or more of our development candidates, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products84% rewritten
  8. 37If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected
  9. 38If we or our collaborators, manufacturers, service providers or other third parties fail to comply with applicable healthcare laws and regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation92% rewritten
  10. 39Our employees, consultants and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
  11. 40Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any medicines that we may develop
  12. 41the inability to commercialize any medicines that we may develop
  13. 42Our internal computer and information systems, or those used by our CROs, CMOs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our development programs
  14. 43We may be unable to adequately protect our information systems from cybersecurity incidents or data breaches, which could result in the disclosure of confidential information, damage our reputation, and subject us to significant financial and legal exposure82% rewritten
  15. 44misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plansNew
  16. 45Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our development candidates outside the United States56% rewritten
  17. 46We, our collaborators and our service providers may be subject to a variety of privacy and data security laws, regulations and contractual obligations, and our failure to comply with them could harm our business50% rewritten

Risks Related to Our Third Party Relationships

  1. 47We expect to rely on third parties to conduct our clinical trials and some aspects of our research, as well as some aspects of our delivery methods, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing77% rewritten
  2. 48Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations
  3. 49litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties
  4. 50We rely, and anticipate that we will rely, on third parties to design, conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business
  5. 51We rely on third parties in the supply and manufacture of our lead candidates and development candidates for our research, preclinical and clinical activities, and may do the same for commercial supplies of our lead or development candidates29% rewritten

Risks Related to Our Personnel, Operations and Growth

  1. 52If we are unable to attract and retain qualified key management and scientists, staff, consultants and advisors, our ability to implement our business plan may be adversely affected
  2. 53We expect to need to expand our research, development, delivery, manufacturing, commercialization, regulatory and future sales and marketing capabilities over time, and as a result, we may encounter difficulties in managing our future growth, which could disrupt our operations44% rewritten

Risks Related to Intellectual Property

  1. 54If we are not able to obtain or protect intellectual property rights related to any of our lead candidates and development candidates, development and commercialization of our development candidates may be adversely affected
  2. 55Our pending patent applications may not issue as patents, and even issued patents may not provide sufficient protection of our RNA editing platform OPERA, our lead candidates and our development candidates
  3. 56We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our development candidates
  4. 57We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful77% rewritten
  5. 58more of our products or certain aspects of our platform technology. Further, a court or administrative body could construe certain patent claims narrowly or refuse to prevent the other party from using the technology at issue on the ground that our patents do not cover the technologyNew
  6. 59Our commercial success depends in part on our ability to develop, manufacture, market and sell our development candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property or proprietary rights of third parties
  7. 60there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock
  8. 61We may not be successful in acquiring or in-licensing necessary rights to key technologies or any development candidates we may develop
  9. 62We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
  10. 63Third parties may assert that our employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets
  11. 64Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
  12. 65We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world
  13. 66Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our RNA editing platform technology, lead candidates and development candidates46% rewritten
  14. 67the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospectsNew
  15. 68If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed21% rewritten
  16. 69Patent terms may be inadequate to protect our competitive position on our development candidates for an adequate amount of time
  17. 70If we do not obtain PTE and data exclusivity for any development candidates we may develop, our business may be materially harmed
  18. 71Intellectual property rights do not necessarily address all potential threats
  19. 72Our use of open source software could impose limitations on our ability to commercialize our development candidates
  20. 73If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
  21. 74Our business could be materially and adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics
  22. 75Our operations are vulnerable to interruption by disasters, terrorist activity, pandemics and other events beyond our control, which could harm our business
  23. 76Litigation costs and the outcome of litigation could have a material adverse effect on our business
  24. 77The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for our stockholders
  25. 78period-to-period fluctuations in our financial results
  26. 79We are incurring and expect to continue to incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies
  27. 80Once we are no longer a smaller reporting company or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results and cash flows
  28. 81If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
  29. 82Our certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
  30. 83require the approval of the holders of at least 66.67% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws
  31. 84We do not anticipate that we will pay any cash dividends in the foreseeable future
  32. 85An active trading market for our common stock may not continue to develop or be sustained and our stockholders may not be able to resell their shares of common stock for a profit, if at all
  33. 86Future sales of shares by existing stockholders could cause our stock price to decline
  34. 87Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval
  35. 88If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
  36. 89We will have broad discretion in the use of our cash and cash equivalents and may invest or spend our cash in ways with which you do not agree and in ways that may not increase the value of your investment
  37. 90Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or development candidates we may develop
  38. 91Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition36% rewritten
  39. 92Our ability to utilize our net operating loss, or NOL, carryforwards and certain other tax attributes may be limited
  40. 93Unfavorable global economic conditions could adversely affect our business, financial condition, results of operations or cash flows
  41. 94Our business may be impacted by macroeconomic conditions, including inflation, rising interest rates and volatile market conditions, and other uncertainties beyond our control, including geopolitical events, such as recent U.S. and Israeli military action in Iran, and effects thereofNew

Other Korro Bio 10-Ks

  • FY2024 10-K risk factors
    99 risks

    Korro Bio faces substantial operating losses and an accumulated deficit of $266.6 million as of December 31, 2024.

    Filed Mar 18, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.